bladder image holder

5th most common cancer in europe and 6th most comon in the US

border
bladder image holder

430,000 new bladder cancer cases diagnosed in 2012 worldwide

border
bladder image holder

3 times more common in men compared to women

border
bladder image holder

highest lifetime treatment costs per patient out of all cancers

border

bladder_logo

Bladder EpiCheck is Nucleix’s first product that includes a panel of 15 DNA methylation biomarkers for detection of bladder cancer.

Bladder EpiCheck is expected to be launched at Q1 2017 in the EU, followed by other markets.

Bladder EpiCheck is not currently approved for clinical use.

Bladder EpiCheck – Performance

Sensitivity

EpiCheck has a very high ability to correctly identify patients with cancer

Specificity

EpiCheck has a very high ability to correctly identify patients without cancer

NPV

EpiCheck negative predictive value means 97% probability of being a true negative**

* Results are based on a clinical evaluation study with 222 bladder cancer patients post-treatment that came for recurrence monitoring. Performed in collaboration with Meir Medical Center, Israel

** Calculated assuming 17.6% prevalence of disease recurrence (as in this cohort)